ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NCNA / dividends
XTLB (46) TRAW (31) DRMA (34) APUS (37) ⌘ Pro Terminal →

NuCana plc (NCNA) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.98 -2.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.97

NuCana plc (NCNA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $4.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NCNA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NCNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NuCana plc (NASDAQ: NCNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.98 (-2.96% 1D, market cap $4.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, NCNA ranks #351 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NCNA compare to XTLB and TRAW in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NCNA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XTLB (XTL Biopharmaceuticals Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $4.0M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, NCNA leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NCNA?
▼

For NuCana plc (NCNA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #351 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.97 (-0.72%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE NCNA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NCNA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY NCNA SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($117.7K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$1.05-3.8% Next Q
Q2 (-2Q)
51
Grade C-$1.01+8.9% Next Q
Q3 (-1Q)
49
Grade D$1.10-10.9% Next Q
Current
46
Grade D$0.98-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NCNA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NCNA currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.22) and Max Pain ($1.03) forces dealer call-delta covering toward $4.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NCNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NCNA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NCNA)

  • ✓Walkthrough of NCNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NCNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.66%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.04H $1.04L $0.98C $0.98VOL 19.2K
RES: $1.55SUP: $0.85SMA50: $1.22SMA200: $1.73
$3.90$3.10$2.30$1.50$0.70RES $1.55SUP $0.85$0.982026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NCNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NCNA Butterfly Map → + Track NCNA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NCNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NCNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NCNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NCNA)

Health Care Rank #351 of 1015 ⚔️ XTLB vs NCNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NCNA vs. XTLB, TRAW, DRMA, APUS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NuCana plc (NCNA) ranks #351 by composite RQD confidence (46/100, grade D) and #954 by equity capitalization ($4.2M). Within this direct 5-issuer industry benchmark cohort, NCNA leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. NCNA currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NCNA ACTIVE
NuCana plc
D 46/100 — — — -2.96% $4.2M Benchmark Subject
XTLB
XTL Biopharmaceuticals Ltd.
D 46/100 — — — +5.60% $4.0M /xtlb-vs-ncna →
TRAW
Traws Pharma Inc.
E 31/100 — — -35.0% +1.45% $4.5M /traw-vs-ncna →
DRMA
Dermata Therapeutics Inc.
E 34/100 — — -35.0% -2.73% $3.8M /drma-vs-ncna →
APUS
Apimeds Pharmaceuticals US Inc.
D- 37/100 — — -6.2% -3.99% $4.6M /apus-vs-ncna →

2. NCNA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

NuCana plc (NCNA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. NCNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NCNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NuCana plc (NASDAQ: NCNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.98 (-2.96% 1D, market cap $4.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, NCNA ranks #351 in composite RQD confidence.

How does NCNA compare to XTLB and TRAW in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NCNA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XTLB (XTL Biopharmaceuticals Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $4.0M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, NCNA leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NCNA?

For NuCana plc (NCNA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #351 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NCNA trading relative to its 50-day, 200-day, and 52-week technical levels?

NCNA last traded at $0.98 (-2.96% on volume of 40,377 shares), positioning the stock -19.67% below its 50-day simple moving average ($1.22) and -43.35% below its 200-day simple moving average ($1.73). Across its 52-week range of $0.95 to $4.55, NCNA sits at the 0.8% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).

Direct Sub-Reports: NCNA RQD Cockpit NCNA 12M Forecast NCNA Earnings & Move NCNA Dividends & DRIP NCNA Insiders & 13F NCNA Whale Options NCNA Profit Sankey NCNA News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

NCNA — NuCana plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

NuCana plc (NCNA) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $0.98 (-2.96% 1D, market capitalization $4.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NuCana plc (NCNA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..0B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.95 – $4.55 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NCNA carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can NCNA sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $4.55 52-week high?
  • Key Question #3: How sensitive is NCNA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NCNA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NuCana plc (NCNA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NCNA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NCNA Bull vs. Bear Conversation Board — What's Your Call at $0.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NCNA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NCNA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.21 (+19.8%)
📌 Pinned Debate

The Forensic Balance Sheet pillar scores 13 / 20, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5, indicating the strongest com

Long NCNA at $1.01 targeting $1.21. The Forensic Balance Sheet pillar scores 13 / 20, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5, indicating the strongest component of the rating is balance-sheet quality.. Institutional whale score is 3/20 and the risk/reward vs. the $0.95 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.87 (-13.9%)
Spot @ $1.01

With ROIC 0%, FCF yield 0%, and a Whale 13F Flow pillar at only 3 / 20, the rating shows no cash generation and little institutional ac

I respect the product at NuCana plc, but the stock at $1.01 is a different story. With ROIC 0%, FCF yield 0%, and a Whale 13F Flow pillar at only 3 / 20, the rating shows no cash generation and little institutional accumulation.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE